Involvement of Tis11b, an AU-rich binding protein, in induction of apoptosis by rituximab in B cell chronic lymphocytic leukemia cells

Leukemia

Volumn 23, Issue 5, 2009, Pages 986-989

  Baou, M ^a   Jewell, A ^b   Muthurania, A ^a   Wickremasinghe, R G ^c   Yong, K L ^c   Carr, R ^d   Marsh, P ^a   Murphy, J J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KINGSTON UNIVERSITY   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRATE RESPONSE FACTOR 1; MESSENGER RNA; RITUXIMAB; SMALL INTERFERING RNA; TRISTETRAPROLIN;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CELL VIABILITY; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION;

EID: 67349209595     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.340     Document Type: Article

References (8)

1. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E et al Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2002; 101: 6-14.
2. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 26: 196-203.
3. Johnson BA, Geha M, Blackwell TK. Similar but distinct effects of the tristetraprolin/Tis11 immediate-early proteins on cell survival. Oncogene 2000; 19: 1657-1664.
4. Lee SK, Kim SB, Kim JS, Moon CH, Han MS, Lee BJ et al. Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines. Int J Cancer 2005; 117: 32-40.
5. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent pathway. Blood 2002; 99: 1314-1319.
6. Brook M, Tchen CR, Santalucia T, McIlrath J, Arthur JS, Saklatvala J et al. Posttranslational regulation of tristetraprolin subcellular localisation and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways. Mol Cell Biol 2006; 26: 2408-2418.
7. Chrestensen CA, Schroeder MJ, Shabanowitz J, Hunt DF, Pelo JW, Worthington MT et al. MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding. J Biol Chem 2004; 279: 10176-10184.
8. Cittera E, Onofri C, D'Apolito M, Cartron G, Cazzaniga G, Zelante L et al. Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. Cancer Immunol Immunother 2005; 54 273-286.